Abstract:Core needle biopsy (CNB) is now more frequently used for the preoperative diagnosis of thyroid nodules. Based on morphology alone, 5–20% of CNB samples cannot be determined as malignant or benign. Compared to fine-needle biopsy (FNB), samples collected by CNB are more accessible for various tests. Therefore, studying biomarkers’ application in distinguishing uncertain CNB samples of thyroid nodules is a practical need. Patients of thyroid nodules with both CNB and matched resected specimens were reviewed. Cases classified as indeterminate lesions, follicular neoplasms, and suspicious for malignancy were retrieved. All CNB samples were stained by immunohistochemistry (IHC) using antibodies against CK19, galectin-3, HBME-1, and CD56 and detected by next-generation sequencing (NGS) using an OncoAim® thyroid cancer multigene assay kit (Singlera Genomics) that detected 26 genes. Taking the resected specimens’ classification as the gold standard, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy of a single biomarker, and various combinations for discriminating malignancy from benignity were calculated. The sensitivity, specificity, PPV, NPV, and accuracy for preoperative malignancy evaluation were as follows. In the cohort of non-follicular-neoplasm-lesions (non-FN-lesion), they were 95.16%, 53.85%, 90.77%, 70.00%, and 88.00% for CK19; 95.16%, 38.46%, 88.06%, 62.50%, and 85.33% for galectin-3; 77.42%, 76.92%, 94.12%, 41.67%, and 58.00% for HBME-1; 66.13%, 100.00%, 100.00%, 38.24%, and 72.00% for CD56; 90.32%, 92.31%, 98.25%, 66.67%, and 90.67% for NGS; and 88.71%, 92.30%, 98.21%, 63.16%, and 89.33% for integrated IHC. In the cohort of follicular neoplasms (FN), they were 30.43%, 77.77%, 77.77%, 30.43%, and 43.75% for CK19; 73.91%, 66.67%, 85.00%, 50.00%, and 71.88% for galectin-3; 26.09%, 88.89%, 85.71%, 32.00%, and 43.75% for HBME-1; 26.09%, 100.00%, 100.00%, 34.62%, and 46.88% for CD56; 52.17%, 88.89%, 92.31%, 42.11%, and 62.50% for NGS; 82.61%, 66.67%, 86.36%, 60.00%, and 78.13% for integrated IHC; and 100%, 66.67%, 88.46%, 100%, and 90.63% for integrated IHC-NGS. The application of biomarkers in distinguishing uncertain CNB samples of thyroid nodules is available and capable. CD56 negative or NGS positive suggests malignancy strongly for both FN and non-FN-lesion, which may be used as a “rule in” tool. The negative predictive value of the integrated IHC and the integrated IHC-NGS implies a high possibility to be benign for non-FN-lesion and FN separately, which can work as a “rule out” tool. Considering the balance of specificity and sensitivity, NGS is the best for non-FN-lesion and the integrated IHC-NGS is the best for FN.

The Diagnostic Utility of Combination of HMGA2 and IMP3 qRT-PCR Testing in Thyroid Neoplasms

Clinical Value of High Frequency Ultrasound Guided FNA and Washout Fluid Thyroglobulin Detection for Diagnosing Lateral Neck Lymph Nodes Metastasis of Thyroid Carcinoma

The Value of Thyroglobulin Measurement in Fine-Needle Aspiration for Diagnosis of Suspicious Lymph Nodes in Patients with Thyroid Carcinoma after Thyroidectomy

Clinical Value of High Frequency Ultrasound Guided Fine Needle Aspirates(fna) and FNA-thyroglobulin Detection for Diagnosing Cervical Metastatic Lymph Nodes in Patients Underwent Thyroidectomy for Papillary Thyroid Carcinoma

Diagnostic Value of Fine-needle Aspiration and Thyroglobulin Measurement in Fine-needle Aspiration for Node Metastasis in Thyroid Carcinoma Before Thyroidectomy

HMGA2 Expression Analysis in Cytological and Paraffin-embedded Tissue Specimens of Thyroid Tumors by Relative Quantitative RT-PCR

Combining Real-Time Elastography with Fine-Needle Aspiration Biopsy to Identify Malignant Thyroid Nodules

HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules

Primary Evaluation of Appling HMGA2 in the Diagnosis of Thyroid Carcinoma

Insulin-Like Growth Factor mRNA Binding Protein 3 (IMP3) is Differentially Expressed in Benign and Malignant Follicular Patterned Thyroid Tumors

Diagnostic Value of Contrast-Enhanced Ultrasound Combined with Fine-Needle Aspiration for Thyroid Cancer

Combined Fine-Needle Aspiration and Selective Intraoperative Frozen Section to Optimize Prediction of Malignant Thyroid Nodules: A Retrospective Cohort Study of More Than 3000 Patients

Predicting Malignancy in Thyroid Nodules with Benign Cytology Results: the Role of Conventional Ultrasound, Shear Wave Elastography and BRAF V600E

A molecular computational model improves the preoperative diagnosis of thyroid nodules

HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions

A Combination of BRAF and EZH1/SPOP/ZNF148 Three-Gene Mutational Classifier Improves Benign Call Rate in Indeterminate Thyroid Nodules

Analysis of BRAFV600E mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies

Application of biomarkers in the diagnosis of uncertain samples of core needle biopsy of thyroid nodules

Diagnostic Efficacy of Ultrasound, Cytology, and BRAF(V600E) Mutation Analysis and Their Combined Use in Thyroid Nodule Screening for Papillary Thyroid Microcarcinoma

High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules

Expression of Cytokeratin19, Galectin-3 and HBME-1 in Thyroid Lesions and Their Differential Diagnoses